S-OA-E
Oral Abstracts - Session E - GVH/GVL
BMT Tandem "Scientific" Meeting
Texas D (Gaylord Texan)
Chairs:
David B. Miklos, MD, PhD
and
John Levine, MD, MS
Disclosures:
D. B. Miklos,
Nothing To Disclose
J. Levine,
Nothing To Disclose
In Vivo T Regulatory Cell Kinetics Are Altered in a Pre-Clinical Model of Chronic Graft-Versus-Host Disease
Nataliya Prokopenko Buxbaum, MD, NIH, NCI;
Donald Eugene Farthing, PhD, NIH, NCI;
Shirin Treadwell, MS, FDA;
Catherine Bare, BS, NIH, NCI;
Veena Kapoor, BS, NIH, NCI;
William Telford, PhD, NIH, NCI;
Ronald Gress, MD, NCI
Early Th1 Immunity Decreases Acute Graft-Versus-Host Disease and Impairs Graft-Versus-Leukemia Effect after Allogeneic Hematopoietic Cell Transplantation
Brian G. Engelhardt, Vanderbilt University Medical Center;
Dae Kwang Jung, BS, Vanderbilt University Medical Center;
Bipin N. Savani, MD, Vanderbilt University Medical Center;
Madan H. Jagasia, MD, MBBS, MS, Vanderbilt University Medical Center;
Adetola A. Kassim, MD, MS, Vanderbilt University Medical Center;
Salyka Sengsayadeth, MD, Vanderbilt University Medical Center;
Sandra Yoder, BS, Vanderbilt University Medical Center;
Michael Rock, PhD, Vanderbilt University Medical Center;
James E. Crowe Jr., MD, Vanderbilt University Medical Center
Higher Mycophenolic Acid (MPA) Trough Levels Result in Lower Day 100 Severe Acute Graft-Versus-Host Disease (aGVHD) without Increased Toxicity in Double-Unit Cord Blood Transplantation (CBT) Recipients
Stephen Harnicar, PharmD, BCOP, BCPS, Memorial Sloan-Kettering Cancer Center;
Doris M. Ponce, MD, Memorial Sloan-Kettering Cancer Center;
Sherry Mathew, PharmD, BCOP, Memorial Sloan-Kettering Cancer Center;
Katherine Evans, BA, Memorial Sloan-Kettering Cancer Center;
Junting Zheng, MS, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Melissa Pozotrigo, PharmD, BCOP, Memorial Sloan-Kettering Cancer Center;
Andromachi Scaradavou, MD, New York Blood Center;
Nancy A Kernan, MD, Memorial Sloan-Kettering Cancer Center;
Nelly G Adel, PharmD, BCOP, BCPS, Memorial Sloan-Kettering Cancer Center;
Juliet N. Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center
Inhibition of Cdk2 Inactivates EZH2 and Induces Epigenetic Regulation of FoxP3 Leading to the Generation of CD8+ Treg and Protection from GvHD
Lequn Li, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Nikolaos Patsoukis, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Anoma Nellore, MD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Vassiliki A. Boussiotis, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School
IL-22 Administration Protects Intestinal Stem Cells from Gvhd
Caroline Lindemans, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Anna Mertelsmann, Memorial Sloan-Kettering Cancer Center;
Jarrod A Dudakov, Memorial Sloan-Kettering Cancer Center;
Enrico Velardi, Memorial Sloan-Kettering Cancer Center;
Guoqiang Hua, Memorial Sloan-Kettering Cancer Center;
Margaret O'Connor, Memorial Sloan-Kettering Cancer Center;
Richard Kolesnick, Memorial Sloan-Kettering Cancer Center;
Marcel R. M. van den Brink, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Alan M. Hanash, MD, PhD, Memorial Sloan-Kettering Cancer Center
Targeting Sag in Donor T Cells As a Novel Strategy for Reducing Gvhd
Nathan Mathewson, University of Michigan Comprehensive Cancer Center;
Tomomi Toubai, M.D., PhD, University of Michigan Comprehensive Cancer Center;
Yaping Sun, Ph.D., University of Michigan Comprehensive Cancer Center;
Ying Wang, MD, University of Michigan Comprehensive Cancer Center;
Katherine Oravecz-Wilson, University of Michigan Comprehensive Cancer Center;
Guoqing Hou, Ph.D, University of Michigan Comprehensive Cancer Center;
Julia Wu, University of Michigan Comprehensive Cancer Center;
Pavan Reddy, M.D., University of Michigan
